Information Provided By:
Fly News Breaks for July 22, 2016
ALXN
Jul 22, 2016 | 07:22 EDT
Jefferies analyst Eun Yang lowered her price target for Alexion Pharmaceuticals to $140 saying it is more likely than not that there will be competition for Soliris in 2021 and beyond. There could be downside to the low $100s for the shares, Yang tells investors in a research note. She continues to find the stock's risk/reward uncompelling and keeps a Hold rating on Alexion.
News For ALXN From the Last 2 Days
There are no results for your query ALXN